Clinical Trial News and Research

RSS

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

H1N1 vaccine will be approved, ready for use by September, WHO says

By September, the first H1N1 (swine) flu vaccines will be approved and ready for use, WHO director of the Initiative for Vaccine Research Marie-Paule Kieny said Thursday, Reuters reports. Kieny also expressed optimism that "vaccine production yields were improving, following a disappointing start that triggered some worries about supplies," the news service writes.

7 Aug 2009

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Two studies conducted by researchers at the University of Illinois at Chicago and Northwestern University have found that commonly used botanicals do not have an effect on hot flashes or on cognitive function in menopausal women.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Cutting-edge imaging research aims to map brain injuries

In the first study of its kind, researchers at Saint Louis University are recruiting patients for a clinical trial that will use cutting-edge imaging equipment to map the brain injuries of combat veterans and civilians, aiming to better understand the nature of their injuries.

5 Aug 2009

Cancer Therapy & Research Center (CTRC) retains status as NCI-designated cancer center

The National Cancer Institute, the nation’s top cancer research organization, has renewed the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio as one of its NCI-designated Cancer Centers for three years. The distinction comes with $5.4 million in new federal funding through 2012 to sustain and grow the cancer center’s rapidly expanding research programs, now consisting of 140 scientists at work on a multitude of cancer projects.

4 Aug 2009

New understanding on Gleevec's limitations

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

4 Aug 2009

Clinical trial to test gene therapy for Alzheimer’s disease

Researchers at the Shiley-Marcos Alzheimer's Disease Research Center at the University of California San Diego are about to launch a Phase 2 clinical trial to test a gene therapy treatment for Alzheimer’s disease (AD) called CERE-110.

4 Aug 2009

Discovery of potential candidate protein for cancer vaccines

Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.

4 Aug 2009

Accelerating the development of new cancer drugs

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.

4 Aug 2009

New method selectively kills metastatic melanoma

An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma – a cancer that is highly resistant to current treatment strategies.

4 Aug 2009

Selective method kills metastatic melanoma cells

An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma - a cancer that is highly resistant to current treatment strategies.

3 Aug 2009

Gene therapy for retinitis pigmentosa

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease.

31 Jul 2009

Surgical treatment of migraine safe and effective

Migraine headaches are a drain - not only on the estimated 30 million Americans who suffer from them, but on the economy, too. Because pain and other symptoms caused by migraine headaches can be quite severe, it is projected that nearly $13 billion is spent every year in headache treatment and loss of time from work, which no one can afford these days.

31 Jul 2009

Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBI

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns.

28 Jul 2009

Seattle Genetics starts Brentuximab Vedotin retreatment trial

Seattle Genetics, Inc. has announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

27 Jul 2009

Improving patients' attention after a stroke could help them recover their motor skills

Scientists in New Zealand say after a stroke improving patients' attention could help them to recover their motor skills.

27 Jul 2009

Improving impaired attention may help patients recover from stroke

It may be possible to improve impaired attention after stroke - which could aid recovery - according to research reported in Stroke: Journal of the American Heart Association.

26 Jul 2009